Escalating Plasmodium falciparum K13 marker prevalence indicative of artemisinin resistance in southern Rwanda.

Welmoed van LoonEmma SchallenbergClement IgiranezaFelix HabarugiraDjibril MbarushimanaFabian NshimiyimanaChristian NgarambeJean Baptiste NtihumbyaJules Minega NdoliFrank P Mockenhaupt

Published in: Antimicrobial agents and chemotherapy (2023)

In 2023, we updated data collected since 2010 on Plasmodium falciparum K13 and MDR1 drug resistance markers in Huye district, southern Rwanda. Artemisinin resistance-associated PfK13 markers occurred in 17.5% of 212 malaria patients (561H, 9.0%; 675V, 5.7%; and 469F, 2.8%), nearly double the frequency from 2019. PfMDR1 N86, linked with lumefantrine tolerance, was close to fixation at 98%. In southern Rwanda, markers signaling resistance to artemisinin and lumefantrine are increasing, albeit at a relatively slow rate.

Keyphrases

plasmodium falciparum
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
multidrug resistant
minimally invasive
big data
deep learning